tiprankstipranks
Advertisement
Advertisement
ResMed price target lowered to $225 from $254 at Baird
PremiumThe FlyResMed price target lowered to $225 from $254 at Baird
25d ago
ResMed price target lowered to $235 from $265 at Stifel
Premium
The Fly
ResMed price target lowered to $235 from $265 at Stifel
25d ago
Analyst Brandon Vazquez Reiterates Buy on ResMed Amid Solid Execution, Margin Expansion, and Attractive Valuation Despite Near-Term Headwinds
Premium
Ratings
Analyst Brandon Vazquez Reiterates Buy on ResMed Amid Solid Execution, Margin Expansion, and Attractive Valuation Despite Near-Term Headwinds
25d ago
ResMed price target lowered to $290 from $302 at KeyBanc
PremiumThe FlyResMed price target lowered to $290 from $302 at KeyBanc
29d ago
ResMed: Buy Rating on Depressed Valuation as Market Overprices Philips and GLP‑1 Risks
Premium
Ratings
ResMed: Buy Rating on Depressed Valuation as Market Overprices Philips and GLP‑1 Risks
1M ago
ResMed initiated with an Overweight at JPMorgan
Premium
The Fly
ResMed initiated with an Overweight at JPMorgan
1M ago
ResMed Officer Sandercock Discloses Ongoing Insider Share Sales Under Rule 144
PremiumCompany AnnouncementsResMed Officer Sandercock Discloses Ongoing Insider Share Sales Under Rule 144
2M ago
ResMed Director Peter Farrell Plans Further Insider Share Sale Under Rule 144
Premium
Company Announcements
ResMed Director Peter Farrell Plans Further Insider Share Sale Under Rule 144
2M ago
Resmed: Strong Market Position and Financial Profile Offer Upside Amid Overstated GLP‑1 and Competitive Risks
Premium
Ratings
Resmed: Strong Market Position and Financial Profile Offer Upside Amid Overstated GLP‑1 and Competitive Risks
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100